ImmunityBio secures up to $320M royalty and equity financing from Oberland Capital; $210M funded at close

ImmunityBio, Inc.

$200M non-dilutive royalty financing closed; additional $100M contingent on FDA approval of Anktiva for NMIBC (PDUFA Apr 23, 2024).
$10M equity private placement at $4.11/share; Oberland gets 5-year option for another $10M.
Nant Capital $505M notes extended to Dec 2025; conversion option at 75% premium to market.
Total 2023 capital raised reaches $850M; proceeds to fund commercialization and pipeline.
Royalty rate: initially 3%-7% of net sales (ex-China); capped at 195% of investment; may step down to 1.5%.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ImmunityBio, Inc. entered into Revenue Interest Purchase Agreement with Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers valued at $200.0 million (effective 2023-12-29).

Action: entry
Counterparty: Infinity SA LLC, an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers
Value: $200.0 million
Effective: 2023-12-29

Exact text from the filing

On December 29, 2023 (the “Closing Date”), ImmunityBio, Inc. (the “Company”), entered into a Revenue Interest Purchase Agreement (the “RIPA”) with Infinity SA LLC (the “Purchaser Agent”), an affiliate of Oberland Capital Management LLC, as collateral agent and administrative agent for the purchasers party thereto (each, a “Purchaser”, and collectively, the “Purchasers”). Pursuant to the RIPA, the Purchasers acquired certain revenue interests (the “Revenue Interests”) from the Company for a gross purchase price of $200.0 million (the “First Payment”) paid at closing.

View on SEC.gov

Browse all material agreements →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001326110-24-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.